ENDRA Life Sciences (NDRA) Q2 2024 earnings summary

Executive summary

• Announced a 1-for-50 reverse stock split and new executive team, including Alexander Tokman as acting CEO and key hires in finance and regulatory affairs, to maintain Nasdaq listing and drive turnaround.

• Outlined six strategic changes: stronger operating team, prioritization, new FDA approach, revised go-to-market for TAEUS liver device, clarified vision, and improved financial execution.

• Advanced U.S. regulatory process for TAEUS technology with FDA alignment and initiated new pilot clinical trials in North America and Europe.

• Expanded intellectual property portfolio to 81 issued patents, with five new patents in Q2 2024.

• No revenue generated as of June 30, 2024; focus remains on developing and commercializing TAEUS technology for non-invasive tissue characterization.

Financial highlights

• Raised $7.3M in net proceeds ($8M gross) from a public offering in June 2024, boosting cash and cash equivalents to $6.4M as of June 30, 2024.

• Operating expenses for Q2 2024 were $2.2M, down from $3M in Q2 2023, mainly due to a 49% reduction in R&D and a 34% drop in sales/marketing costs.

• Net loss for Q2 2024 was $2.23M, an improvement from $2.56M in Q2 2023; accumulated deficit reached $96.94M.

• No revenue or cost of goods sold reported for the period.

• Working capital as of June 30, 2024 was $5.36M.

Outlook and guidance

• Targeting completion of clinical study in 2024 and De Novo FDA submission for TAEUS liver device by mid-2025.

• Strategic roadmap to be developed over the next 6–12 months, exploring organic and licensing growth opportunities.

• Ongoing need for additional capital to fund operations and commercialization; current cash is insufficient for long-term needs.